|
|
Pavmed Inc (NASDAQ: PAVM) |
|
Price: $0.6500
$0.01 
0.806%
|
| Day's High:
| $0.66
| Week Perf:
| 8.33 %
|
| Day's Low: |
$ 0.62 |
30 Day Perf: |
-9.77 % |
| Volume (M): |
53 |
52 Wk High: |
$ 3.50 |
| Volume (M$): |
$ 34 |
52 Wk Avg: |
$1.39 |
| Open: |
$0.66 |
52 Wk Low: |
$0.57 |
|
|
| Market Capitalization (Millions $) |
29 |
| Shares
Outstanding (Millions) |
44 |
| Employees |
18 |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
10 |
| Cash Flow (TTM) (Millions $) |
-26 |
| Capital Exp. (TTM) (Millions $) |
0 |
Pavmed Inc
Pavmed Inc is a medical device company that focuses on developing and commercializing innovative products to address unmet medical needs. The company uses a unique business model, leveraging a network of collaborators and expertise to rapidly develop and bring to market new medical technologies. Pavmed aims to improve patient outcomes and reduce healthcare costs through its product portfolio, which includes devices for various medical applications such as oncology, orthopedics, and wound care. The company's approach is driven by a combination of in-house expertise, acquisitions, and collaborations with established medical institutions.
Company Address: 360 Madison Avenue New York 10017 NY
Company Phone Number: 813-1828 Stock Exchange / Ticker: NASDAQ PAVM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Pavmed Inc
In the world of stock markets, it is crucial for investors to stay informed about the performance of companies. Pavmed Inc, a prominent Medical Equipment & Supplies company, recently released its fiscal year report, providing interesting insights into its financial health. While the company experienced an exponential increase in losses over the fiscal span closing March 31, 2024, it also exhibited robust revenue growth. This article highlights key facts from Pavmed Inc's report, shedding light on the company's position within the Medical Equipment & Supplies sector.
Increased Losses Per Share
One striking fact from Pavmed Inc's financial report is the significant increase in the loss per share. In comparison to $-0.18 per share recorded a year ago, the latest fiscal year reported a loss of $-2.62 per share. Furthermore, the report also reveals an increased loss from $-0.15 per share from the previous reporting period. While these figures may concern investors, it is essential to balance them against the company's revenue growth.
|
| Pavmed Inc
Pavmed Inc, a renowned Medical Equipment & Supplies company, has recently announced its financial results for the October to December 31, 2023 period. These results highlight significant improvements in various key metrics, including reduced losses per share, increased income per share, and a remarkable surge in revenue. This article aims to interpret these financial results and discuss how they are likely to impact Pavmed Inc's future prospects.
Reduced Losses and Increased Income:
In the specified period, Pavmed Inc demonstrated a strong improvement in their financial position as they decreased their loss per share from $-0.21 to $-0.15 compared to the previous year. Moreover, their income per share also exhibited growth, rising from $-0.16 to an undisclosed positive value. These positive developments suggest that the company has been successfully implementing measures to enhance operational efficiency and cost management. By focusing on streamlining their operations, Pavmed Inc has effectively reduced their losses and set the stage for potential profitability in the future.
|
| Pavmed Inc
Pavmed Inc, a medical equipment and supplies company, has seen some notable shifts in its share price and financial performance over the past few weeks. In the last five trading days, Pavmed Inc shares recorded a solid gain of 6.38%. However, over the past 30 days, the shares experienced a decline of -9.41%. Currently, the shares are trading only 15.2% above their 52-week low.
Despite these fluctuations in share price, Pavmed Inc announced a very impressive revenue improvement of 1103.947% year on year to $0.92 million in the third quarter of the 2023 earnings season. However, the company incurred a loss of -$0.16 per share during this period. While Pavmed Inc experienced faster business growth compared to its peers in the medical equipment and supplies industry, with two-thirds of its industry counterparts seeing an average business improvement of 5.23% in the same reporting period, the company's deficit increased from -$0.14 per share in the previous reporting period.
|
| Pavmed Inc
Pavmed Inc Achieves Promising Revenue Growth and Narrowed Losses, Setting Positive Outlook for Stock Market
In the ever-evolving landscape of the stock market, some companies become beacons of hope and promise. Pavmed Inc is one such company, demonstrating remarkable achievements and resilient growth in the second quarter of 2023.
During this period, Pavmed Inc reported an impressive revenue of $0.329 million, marking a significant increase compared to the same quarter in the previous year. This upward trajectory is a testament to the company's strong business strategy and the effectiveness of its products or services. Investors can take solace in the fact that Pavmed Inc's revenue stream is flourishing, indicating a solid foundation for future growth.
|
| Pavmed Inc
Pavmed Inc is a medical device company focused on developing and commercializing a wide range of products to address unmet needs in medical markets. The company's portfolio includes products for vascular access, tissue ablation, and infection control, as well as orthopedic implants and devices for children's health. Despite its innovative product range, Pavmed Inc has struggled to generate profitability in recent years, recording a cumulative net loss of $-106 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on equity (ROE) of -461.6%.
Compared to other companies in the Medical Equipment & Supplies industry, Pavmed Inc has struggled to achieve a high ROE, as 125 other companies had a higher overall ranking in this metric. However, the company's ROE ranking has improved since the fourth quarter of 2022, advancing to 3185 in the first quarter of 2023 from 4260 in the previous quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.52 $ |
| Revenues (TTM) |
0.1 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.02 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.52 $
|
| Revenues (TTM) |
0.1 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.02 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
18.83%